MCID: OCL006
MIFTS: 55

Ocular Hypertension

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Ocular Hypertension

MalaCards integrated aliases for Ocular Hypertension:

Name: Ocular Hypertension 12 55 44 15 73
Hypertension, Ocular 40

Classifications:



External Ids:

Disease Ontology 12 DOID:9282
ICD10 33 H40.05
ICD9CM 35 365.04
MeSH 44 D009798
NCIt 50 C3285
SNOMED-CT 68 4210003
UMLS 73 C0028840

Summaries for Ocular Hypertension

Disease Ontology : 12 An eye disease that is characterized by elevated intraocular pressure in the absence of optic nerve damage or visual field loss.

MalaCards based summary : Ocular Hypertension, also known as hypertension, ocular, is related to open-angle glaucoma and glaucoma, primary open angle, and has symptoms including eye manifestations An important gene associated with Ocular Hypertension is MYOC (Myocilin), and among its related pathways/superpathways are Focal Adhesion and Pathways in cancer. The drugs Travoprost and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 76 Ocular hypertension is the presence of elevated fluid pressure inside the eye (intraocular pressure),... more...

Related Diseases for Ocular Hypertension

Diseases related to Ocular Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Related Disease Score Top Affiliating Genes
1 open-angle glaucoma 31.0 MYOC OPTN PTGFR TMCO1
2 glaucoma, primary open angle 30.9 MYOC OPTN TMCO1
3 low tension glaucoma 29.9 MYOC OPTN RHO
4 optic nerve disease 29.7 MYOC OPN4 OPTN
5 glaucoma 1, open angle, a 29.3 MYOC OPTN
6 glaucoma 3, primary congenital, a 11.3
7 glaucoma 3, primary infantile, b 11.0
8 cataract 10.2
9 uveitis 10.2
10 exfoliation syndrome 10.0
11 pharynx squamous cell carcinoma 10.0 AKT1 PTEN
12 neuropathy 10.0
13 macular retinal edema 10.0
14 endometrial adenocarcinoma 9.9 AKT1 PTEN PTGFR
15 excessive tearing 9.9 MYOC OPTN
16 glaucoma, normal tension 9.9
17 borderline glaucoma 9.9
18 macular dystrophy, dominant cystoid 9.9
19 retinal vein occlusion 9.9
20 ischemia 9.9
21 osteoporosis 9.8 CA2 FOS HSD11B1 JUN NR3C1
22 breast adenocarcinoma 9.8 AKT1 FOS PTEN
23 aging 9.8 AKT1 JUN PTEN
24 retinal detachment 9.8
25 arthritis 9.8
26 retinal ischemia 9.8
27 thrombosis 9.8
28 nephrotic syndrome 9.8
29 scleritis 9.8
30 cavernous sinus thrombosis 9.8
31 retinal degeneration 9.8
32 anterior uveitis 9.8
33 intracranial hypertension 9.8
34 alzheimer disease 9.6
35 keratitis, hereditary 9.6
36 lymphoma, hodgkin, classic 9.6
37 megalocornea 9.6
38 glaucoma-related pigment dispersion syndrome 9.6
39 macular degeneration, age-related, 1 9.6
40 lymphoma, non-hodgkin, familial 9.6
41 anxiety 9.6
42 lung cancer susceptibility 3 9.6
43 leukemia, acute lymphoblastic 9.6
44 graft-versus-host disease 9.6
45 diabetes mellitus 9.6
46 ischemic optic neuropathy 9.6
47 keratoconus 9.6
48 keratopathy 9.6
49 leukemia 9.6
50 lymphoma 9.6

Comorbidity relations with Ocular Hypertension via Phenotypic Disease Network (PDN):


Glaucoma, Primary Open Angle

Graphical network of the top 20 diseases related to Ocular Hypertension:



Diseases related to Ocular Hypertension

Symptoms & Phenotypes for Ocular Hypertension

UMLS symptoms related to Ocular Hypertension:


eye manifestations

MGI Mouse Phenotypes related to Ocular Hypertension:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 AKT1 CA2 EPO FKBP5 FOS HSD11B1
2 immune system MP:0005387 10.23 AKT1 CA2 EPO FOS HSD11B1 JUN
3 cellular MP:0005384 10.22 AKT1 EPO FOS HSD11B1 JUN NR3C1
4 cardiovascular system MP:0005385 10.19 AKT1 EPO HSD11B1 JUN NR3C1 PTEN
5 endocrine/exocrine gland MP:0005379 10.16 AKT1 CA2 FOS HSD11B1 JUN NR3C1
6 hematopoietic system MP:0005397 10.15 AKT1 EPO FOS HSD11B1 JUN NR3C1
7 mortality/aging MP:0010768 10.11 AKT1 CA2 EPO FKBP5 FOS JUN
8 nervous system MP:0003631 10.06 AKT1 CA2 FOS HSD11B1 JUN NR3C1
9 integument MP:0010771 10.03 AKT1 EPO FOS HSD11B1 JUN NR3C1
10 normal MP:0002873 9.96 AKT1 EPO FKBP5 FOS JUN MYOC
11 liver/biliary system MP:0005370 9.95 AKT1 EPO HSD11B1 JUN NR3C1 PTEN
12 respiratory system MP:0005388 9.7 AKT1 CA2 EPO HSD11B1 JUN NR3C1
13 skeleton MP:0005390 9.61 AKT1 CA2 EPO FOS JUN NR3C1
14 vision/eye MP:0005391 9.17 FOS JUN MYOC OPN4 PTEN RHO

Drugs & Therapeutics for Ocular Hypertension

Drugs for Ocular Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 288)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Travoprost Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 157283-68-6 5282226
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
3
Prednisolone phosphate Approved, Vet_approved Phase 4,Not Applicable 302-25-0
4
Prednisolone Approved, Vet_approved Phase 4,Not Applicable 50-24-8 5755
5
Methylprednisolone Approved, Vet_approved Phase 4,Not Applicable 83-43-2 6741
6
Methylprednisolone hemisuccinate Approved Phase 4,Not Applicable 2921-57-5
7
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155206-00-1 5311027
8
Latanoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130209-82-4 5311221 5282380
9
Timolol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 26839-75-8 33624 5478
10
Dorzolamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120279-96-1 5284549 3154
11
Ketorolac Approved Phase 4,Not Applicable 66635-83-4, 74103-06-3 3826
12
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 216974-75-3
13
Acetazolamide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-66-5 1986
14
Topiramate Approved Phase 4 97240-79-4 5284627
15
Brinzolamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 138890-62-7 68844
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-02-2 5743
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 1177-87-3
18
Apraclonidine Approved Phase 4,Phase 3,Not Applicable 66711-21-5 2216
19
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
20
Pilocarpine Approved, Investigational Phase 4,Phase 3,Not Applicable 54-71-7, 92-13-7 5910
21
Dipivefrin Approved Phase 4,Phase 3,Not Applicable 52365-63-6 3105
22
Sorbitol Approved Phase 4 50-70-4 5780
23
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
24
Carteolol Approved Phase 4,Phase 3,Phase 1 51781-06-7 2583
25
Loteprednol Approved, Experimental Phase 4 82034-46-6, 129260-79-3 9865442 444025
26
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
27
Clonidine Approved Phase 4 4205-90-7 2803
28
Diclofenac Approved, Vet_approved Phase 4,Not Applicable 15307-86-5 3033
29
Nitrous oxide Approved, Vet_approved Phase 4,Early Phase 1 10024-97-2 948
30 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
31
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
32
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
33
Choline Approved, Nutraceutical Phase 4 62-49-7 305
34
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 11103-57-4, 68-26-8 445354
35
Prednisolone hemisuccinate Experimental Phase 4,Not Applicable 2920-86-7
36
Maleic acid Experimental Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 110-16-7 444266
37 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Neuroprotective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
39 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable
40 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Not Applicable
41 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
43 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
44 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Not Applicable
45 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
46 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Not Applicable
48 Antiemetics Phase 4,Phase 3,Not Applicable
49 Methylprednisolone acetate Phase 4,Not Applicable
50 Prednisolone acetate Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1240)
# Name Status NCT ID Phase Drugs
1 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
2 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4 Prednisolone 1% topical eye drops
3 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose Unknown status NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
4 Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy Unknown status NCT00442312 Phase 4 Combigan Ophthalmic Solutiom
5 Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG Unknown status NCT02231515 Phase 4
6 Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom Unknown status NCT01125306 Phase 4
7 Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Unknown status NCT02471105 Phase 4 Preserved Bimatoprost 0.01%;Tafluprost Unit Dose Preservative Free 15microgram/ml
8 Glaucoma Treatment Using Focused Ultrasound in Open Angle Glaucoma Patients Unknown status NCT02789293 Phase 4
9 The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma Unknown status NCT02388360 Phase 4 topical prostaglandin analogs
10 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
11 Evaluation of the XEN Implant in Moderate POAG Subjects Unknown status NCT02006693 Phase 4
12 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
13 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
14 The Effect of "Eye Drop Guide" on the Success Rate of Eye Drops Self-instillation in Glaucoma Patients Unknown status NCT01704248 Phase 4
15 Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
16 Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma Unknown status NCT01401088 Phase 4
17 Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery Unknown status NCT01229202 Phase 4 Bevacizumab
18 Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure Unknown status NCT00796198 Phase 4 Xalatan+Cosopt;Xalatan
19 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
20 Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery Unknown status NCT00468429 Phase 4 Subconjunctival Bevacizumab
21 Ologen (OculusGen)-Glaucoma MMC Control Trial in India Unknown status NCT00449098 Phase 4 Trabeculectomy with MMC
22 The Effect of Education on Patient Compliance Unknown status NCT00376974 Phase 4
23 A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Unknown status NCT00326079 Phase 4
24 Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma Unknown status NCT01446497 Phase 4 Brimonidine/Timolol mixed combination;Timolol
25 Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
26 PASCAL Trabeculoplasty Unknown status NCT00804323 Phase 4
27 Relationship Between Topiramate Use and Ocular Angle Status Unknown status NCT00153699 Phase 4 Topiramate
28 Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma Unknown status NCT01494974 Phase 4
29 An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Completed NCT01979913 Phase 4 Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
30 Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension Completed NCT00300079 Phase 4 brinzolamide 1.0%
31 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension Completed NCT01655758 Phase 4 0.5% timolol;timolol-dorzolamide fixed combination;Latanoprost;Travoprost;Bimatoprost
32 Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study Completed NCT01975714 Phase 4 Preservative-free latanoprost;Preservative-free bimatoprost
33 Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension Completed NCT00061503 Phase 4 Travoprost
34 Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension Completed NCT02571712 Phase 4 bimatoprost 0.03% plus timolol 0.5%
35 Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Completed NCT01298700 Phase 4 bimatoprost 0.01% ophthalmic solution;bimatoprost 0.03% ophthalmic solution
36 Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
37 Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects Completed NCT00735449 Phase 4 Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%;timolol maleate 0.5%;latanoprost 0.005%
38 A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension Completed NCT00471380 Phase 4 travoprost 0.004% and brinzolamide 1%;fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle
39 Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate
40 A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma Completed NCT00647101 Phase 4 Latanoprost
41 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed NCT00330577 Phase 4 timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears)
42 Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension Completed NCT03395535 Phase 4 Primary Medical Treatment Pathway
43 Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) Completed NCT02167035 Phase 4 Combigan Two Times Daily (BID);Simbrinza Three Times Daily (TID)
44 Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP) Completed NCT01162603 Phase 4 TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS
45 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
46 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
47 Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4 Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution
48 Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution Completed NCT02325518 Phase 4 Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
49 Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost Completed NCT01443988 Phase 4 Travoprost
50 Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed Combination Completed NCT00941096 Phase 4 Bimatoprost and Bimatoprost/Timolol fixed combination.

Search NIH Clinical Center for Ocular Hypertension

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: ocular hypertension

Genetic Tests for Ocular Hypertension

Anatomical Context for Ocular Hypertension

MalaCards organs/tissues related to Ocular Hypertension:

41
Eye, Endothelial, Retina, Testes, Lung, Pituitary, Adrenal Gland

Publications for Ocular Hypertension

Articles related to Ocular Hypertension:

(show top 50) (show all 1033)
# Title Authors Year
1
Intravenous Hypertonic Saline to Lower Intraocular Pressure in Ocular Hypertension and Primary Open-angle and Exfoliation Glaucoma. ( 29750719 )
2018
2
Resveratrol ameliorates disorders of mitochondrial biogenesis and dynamics in a rat chronic ocular hypertension model. ( 29894715 )
2018
3
Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension. ( 29846910 )
2018
4
Knockout of tissue transglutaminase ameliorates TGFI^2-induced ocular hypertension: A novel therapeutic target for glaucoma? ( 29535003 )
2018
5
What We Have Learned From the Ocular Hypertension Treatment Study. ( 29861092 )
2018
6
P2X7 receptor antagonist protects retinal ganglion cells by inhibiting microglial activation in a rat chronic ocular hypertension model. ( 29207073 )
2018
7
Expression and activation of mitogen activated protein kinases in the optic nerve head in a rat model of ocular hypertension. ( 29408550 )
2018
8
Ocular Hypertension/Glaucoma in Minipigs: Episcleral Veins Cauterization and Microbead Occlusion Methods. ( 29190016 )
2018
9
Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension. ( 29873009 )
2018
10
Steroid-induced ocular hypertension in the pediatric age group. ( 29554813 )
2018
11
The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells. ( 29398521 )
2018
12
Noninvasive evaluation of cerebrospinal fluid pressure in ocular hypertension: a preliminary study. ( 29575652 )
2018
13
Clinical outcomes of patterned laser trabeculoplasty as adjuvant therapy in open angle glaucoma and ocular hypertension. ( 29675383 )
2018
14
Transforming growth factor I^2 (TGFI^2) signaling plays a key role in glucocorticoid-induced ocular hypertension. ( 29743238 )
2018
15
Methods to Induce Chronic Ocular Hypertension: Reliable Rodent Models as a Platform for Cell Transplantation and Other Therapies. ( 29637819 )
2018
16
Prevalence of Ocular Hypertension and Glaucoma as Well as Associated Factors in Graves' Orbitopathy. ( 29557835 )
2018
17
Noninvasive Detection of Mitochondrial Dysfunction in Ocular Hypertension and Primary Open-angle Glaucoma. ( 29750714 )
2018
18
Steroid-induced protracted severe ocular hypertension in a 14-year-old girl. ( 29950368 )
2018
19
Calcium channels are involved in EphB/ephrinB reverse signalinga89induced apoptosis in a rat chronic ocular hypertension model. ( 29207174 )
2018
20
The Microbead Occlusion Model of Ocular Hypertension in Mice. ( 29190015 )
2018
21
Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. ( 29669171 )
2018
22
What We Have Learned From the Ocular Hypertension Treatment Study. ( 29759296 )
2018
23
Glucocorticoid receptor GRI^ regulates glucocorticoid-induced ocular hypertension in mice. ( 29339763 )
2018
24
Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension. ( 29761382 )
2018
25
Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. ( 29194198 )
2018
26
Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride. ( 29802759 )
2018
27
A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma. ( 29802818 )
2018
28
The effects of repeated Ozurdex injections on ocular hypertension. ( 29662300 )
2018
29
Ocular hypertension in patients with central/hemicentral retinal vein occlusions: cumulative prevalence and management. ( 30046535 )
2018
30
Estimating Ocular Hypertension and Glaucoma With Optic Nerve Tortuosity on Conventional Orbital Magnetic Resonance Imaging. ( 30078397 )
2018
31
Cystoid macular edema following selective laser trabeculoplasty in a patient with ocular hypertension. ( 30105491 )
2018
32
Anterior Segment Optical Coherence Tomography Analysis of Iris Morphometric Changes Induced by Prostaglandin Analogues Treatment in Patients with Primary Open Angle Glaucoma or Ocular Hypertension. ( 30123376 )
2018
33
In-the-bag multifocal intraocular lens causing pigment dispersion and refractory secondary ocular hypertension. ( 30127166 )
2018
34
LATE-ONSET OCULAR HYPERTENSION AFTER VITRECTOMY: A Multicenter Study of 6,048 Eyes. ( 30161094 )
2018
35
A Long-term Safety Study of Latanoprost in Pediatric Patients With Glaucoma and Ocular Hypertension: A Prospective Cohort Study. ( 30194929 )
2018
36
Chronic ocular hypertension in rabbits induced by limbal buckling. ( 30196271 )
2018
37
Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension. ( 30209441 )
2018
38
Contribution of autophagy to ocular hypertension and neurodegeneration in the DBA/2J spontaneous glaucoma mouse model. ( 30210817 )
2018
39
Secondary Ocular Hypertension and the Risk of Glaucoma Surgery After Dexamethasone Intravitreal Implant in Routine Clinical Practice. ( 30222802 )
2018
40
Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. ( 30234748 )
2018
41
Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant. ( 30266279 )
2018
42
Efficacy of the combination of carteolol hydrochloride + latanoprost in the treatment of glaucoma and ocular hypertension. ( 30295543 )
2018
43
OCULAR HYPERTENSION AFTER INTRAVITREAL INJECTION OF 2-MG TRIAMCINOLONE. ( 30308561 )
2018
44
Etidronate protects chronic ocular hypertension induced retinal oxidative stress and promotes retinal ganglion cells growth through IGF-1 signaling pathway. ( 30326214 )
2018
45
The assessment of structural changes on optic nerve head and macula in primary open angle glaucoma and ocular hypertension. ( 30364206 )
2018
46
Time Course Changes of the Mechanical Properties of the Iris Pigment Epithelium in a Rat Chronic Ocular Hypertension Model. ( 30420963 )
2018
47
Diffusion Tensor Imaging Detects Microstructural Differences of Visual Pathway in Patients With Primary Open-Angle Glaucoma and Ocular Hypertension. ( 30459581 )
2018
48
Assessment of the Impact of an Endpoint Committee in the Ocular Hypertension Treatment Study. ( 30471242 )
2018
49
Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications. ( 30477719 )
2018
50
Incidence of and risk factors for secondary ocular hypertension in moderate to severe infectious ulcerative keratitis. ( 30498329 )
2018

Variations for Ocular Hypertension

Expression for Ocular Hypertension

Search GEO for disease gene expression data for Ocular Hypertension.

Pathways for Ocular Hypertension

Pathways related to Ocular Hypertension according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.82 AKT1 FOS JUN PTEN RHO
2 12.76 AKT1 EPO FOS JUN PTEN
3
Show member pathways
12.51 AKT1 FOS JUN PTEN
4
Show member pathways
12.45 AKT1 FOS JUN PTEN
5
Show member pathways
12.32 AKT1 FOS JUN PTGFR
6
Show member pathways
12.3 AKT1 FOS JUN PTEN
7
Show member pathways
12.29 AKT1 FOS JUN PTEN
8
Show member pathways
12.28 AKT1 FOS JUN NR3C1 PTEN
9
Show member pathways
12.22 AKT1 FOS JUN PTEN
10 12.05 AKT1 FOS JUN PTEN
11
Show member pathways
12.01 AKT1 FOS JUN
12 12.01 AKT1 JUN PTEN RHO
13 12 AKT1 FOS JUN
14 11.98 AKT1 FOS JUN
15
Show member pathways
11.96 AKT1 FOS JUN
16
Show member pathways
11.96 AKT1 FOS JUN
17
Show member pathways
11.96 AKT1 FOS JUN PTEN
18 11.92 AKT1 JUN PTEN
19
Show member pathways
11.91 AKT1 FOS JUN
20
Show member pathways
11.9 AKT1 FOS JUN
21 11.89 AKT1 FOS JUN
22 11.85 AKT1 FOS JUN
23 11.8 AKT1 FKBP5 PTEN
24 11.79 AKT1 JUN PTEN
25
Show member pathways
11.76 AKT1 FOS JUN
26
Show member pathways
11.76 AKT1 EPO FOS JUN PTEN
27 11.65 AKT1 FOS JUN NR3C1
28 11.62 AKT1 FOS JUN
29 11.6 AKT1 FOS JUN
30 11.59 AKT1 FOS JUN
31
Show member pathways
11.57 FOS JUN NR3C1
32
Show member pathways
11.55 AKT1 FOS JUN
33 11.51 AKT1 FOS JUN NR3C1
34 11.48 AKT1 JUN PTEN
35
Show member pathways
11.48 AKT1 JUN NR3C1
36 11.46 AKT1 FOS JUN
37 11.4 AKT1 FOS JUN
38 11.37 AKT1 EPO FOS JUN
39 11.3 FOS JUN NR3C1
40 11.28 FOS JUN PTEN
41 11.15 FOS JUN NR3C1
42
Show member pathways
11.14 AKT1 FOS JUN
43 10.94 AKT1 FOS
44 10.94 AKT1 FOS JUN
45 10.94 AKT1 FKBP5 FOS JUN NR3C1
46 10.91 CA2 FOS JUN NR3C1
47 10.74 FOS JUN
48 10.58 OPN4 RHO

GO Terms for Ocular Hypertension

Cellular components related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor AP-1 complex GO:0035976 8.62 FOS JUN

Biological processes related to Ocular Hypertension according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 AKT1 EPO JUN PTEN PTGFR
2 positive regulation of cell proliferation GO:0008284 9.83 AKT1 EPO JUN PTEN PTGFR
3 response to organic cyclic compound GO:0014070 9.7 FOS JUN PTEN
4 response to lipopolysaccharide GO:0032496 9.67 EPO FOS JUN PTGFR
5 positive regulation of osteoclast differentiation GO:0045672 9.54 CA2 FOS
6 cellular response to light stimulus GO:0071482 9.51 OPN4 RHO
7 response to muscle stretch GO:0035994 9.49 FOS JUN
8 protein-chromophore linkage GO:0018298 9.48 OPN4 RHO
9 cellular response to cadmium ion GO:0071276 9.43 AKT1 FOS JUN
10 negative regulation of cell size GO:0045792 9.4 AKT1 PTEN
11 cellular response to reactive oxygen species GO:0034614 9.33 AKT1 FOS JUN
12 cellular response to decreased oxygen levels GO:0036294 9.32 AKT1 PTEN
13 response to organic substance GO:0010033 9.26 AKT1 CA2 JUN PTEN
14 aging GO:0007568 9.02 AKT1 EPO FOS JUN PTEN

Molecular functions related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled photoreceptor activity GO:0008020 9.16 OPN4 RHO
2 photoreceptor activity GO:0009881 8.96 OPN4 RHO
3 11-cis retinal binding GO:0005502 8.8 OPN4 RHO RLBP1

Sources for Ocular Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....